한글목차

펩티드 기반 대사성 질환 치료제 시장 규모는 최근 급성장하고 있습니다. 2025년 341억 달러에서 2026년에는 390억 5,000만 달러에 이르고, CAGR 14.5%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장 요인으로는 2형 당뇨병 유병률 증가, 리라글루티드 및 엑세나타이드 치료의 초기 단계 성공, 펩타이드 의약품의 임상적 유효성 확립, 선진국의 비만율 증가, 대사 경로에 대한 이해의 심화 등을 들 수 있습니다.

펩티드 기반 대사성 질환 치료제 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 637억 달러에 이르고, CAGR은 13.0%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 전 세계 비만 부담 증가, 세마글루티드 및 차세대 펩타이드 채택 증가, 대사성 질환 치료제 파이프라인에 대한 투자 확대, 장기적인 체중 관리 솔루션에 대한 수요 증가, 펩타이드 약물 전달 시스템의 발전 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 GLP-1 수용체 작용제 치료의 도입 증가, 펩타이드 기반 비만 관리에 대한 관심 증가, 지속형 주사제 펩타이드 제제의 확대, 복합 펩타이드 요법의 사용 증가, 환자 친화적인 대사 치료에 대한 수요 증가 등을 들 수 있습니다.

비만 유병률 증가는 향후 몇 년 동안 펩타이드 기반 대사성 질환 치료제 시장의 성장을 견인할 것으로 예측됩니다. 비만은 체지방이 과도하게 축적되어 건강에 심각한 위험을 초래하는 의학적 상태입니다. 비만 사례 증가는 좌식 생활, 부적절한 식습관, 유전적 요인, 고칼로리 식습관을 조장하고 신체 활동을 제한하는 환경적 영향에 기인합니다. 펩타이드 기반 대사 장애 치료제는 펩타이드를 이용하여 대사 과정을 조절하고, 인슐린 감수성을 높이고, 식욕을 조절하여 비만과 같은 상태를 관리하도록 설계되었습니다. 이를 통해 환자의 건강 상태를 개선하고 이러한 만성 질환과 관련된 장기적인 위험을 줄일 수 있습니다. 예를 들어, 영국 정부 기관인 Office for Health Improvement and Disparities(Office for Health Improvement and Disparities)에 따르면, 2024년 12월 기준 임신 초기 비만 여성 비율은 2022-2023년 25.4%, 2023-2024년 26.2%로 소폭 상승했습니다. 26.2%로 소폭 상승했습니다. 이러한 비만 유병률 증가는 펩타이드 기반 대사성 질환 치료제 시장의 성장을 견인하고 있습니다.

펩타이드 기반 대사성 질환 치료제 시장의 주요 기업들은 미충족 수요에 대응하고 환자의 치료 옵션을 확대하기 위해 항당뇨병 바이오시밀러를 포함한 혁신적인 펩타이드 기반 치료제 개발에 집중하고 있습니다. 펩타이드 기반 항당뇨병 바이오시밀러는 기존 펩타이드 기반 당뇨병 치료제를 모방하도록 설계된 치료제로, 기존 의약품과 동등한 효능과 안전성 프로파일을 제공함과 동시에 경쟁력 있는 가격 전략을 통해 치료비 절감의 가능성을 가지고 있습니다. 예를 들어, 2024년 1월 인도에 본사를 둔 제약회사 글렌마크 파마슈티컬스(Glennmark Pharmaceuticals)는 인도에서 널리 사용되는 항당뇨병제 리라글루티드의 바이오시밀러 버전인 릴라핏(LilaFit)을 출시했습니다. 이는 글루카곤 유사 펩타이드-1 수용체 작용제(GLP-1 RA)의 범주에 속합니다. 이 계열의 약물은 혈당 조절에 중요한 역할을 하는 천연 GLP-1 호르몬의 기능을 모방합니다. 해당 바이오시밀러는 임상시험을 통해 혈당 매개변수 개선, 체중감량 촉진, 심혈관 안전성 향상에 대한 유효성이 확인되었습니다. 이러한 장점은 당뇨병 및 비만, 심혈관 질환과 같은 관련 질환의 관리에 필수적입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Peptide-based metabolic disorder therapeutics are pharmaceutical treatments made from peptides, which are short chains of amino acids, that specifically target and influence biological pathways associated with metabolic disorders such as diabetes, obesity, and related conditions. These therapies aim to regulate hormone levels, improve insulin sensitivity, control appetite, and manage glucose metabolism, with the goal of enhancing patient outcomes and quality of life.

The main types of drugs for peptide-based metabolic disorders include liraglutide, exenatide, and others. Liraglutide belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists, which replicate the action of natural GLP-1, a hormone that controls blood sugar levels by promoting insulin secretion and suppressing glucagon release. It is used for lysosomal storage diseases, diabetes, obesity, hypercholesterolemia, and other conditions. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have influenced the peptide based metabolic disorders therapeutics market by raising costs for imported active pharmaceutical ingredients, peptide synthesis reagents, and specialized manufacturing equipment. These impacts are most evident in branded peptide drugs and hospital pharmacy distribution channels, particularly across North America and Europe where cross-border sourcing is common. Higher costs have affected pricing and supply timelines. However, tariffs have also encouraged local manufacturing, contract production partnerships, and supply chain diversification.

The peptide based metabolic disorders therapeutics market research report is one of a series of new reports from The Business Research Company that provides peptide based metabolic disorders therapeutics market statistics, including peptide based metabolic disorders therapeutics industry global market size, regional shares, competitors with a peptide based metabolic disorders therapeutics market share, detailed peptide based metabolic disorders therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide based metabolic disorders therapeutics industry. This peptide based metabolic disorders therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide based metabolic disorders therapeutics market size has grown rapidly in recent years. It will grow from $34.1 billion in 2025 to $39.05 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increasing prevalence of type 2 diabetes, early success of liraglutide and exenatide therapies, growing clinical validation of peptide drugs, rising obesity rates in developed economies, improved understanding of metabolic pathways.

The peptide based metabolic disorders therapeutics market size is expected to see rapid growth in the next few years. It will grow to $63.7 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to expanding global obesity burden, increasing adoption of semaglutide and next-generation peptides, rising investment in metabolic disorder drug pipelines, growing demand for long-term weight management solutions, advancements in peptide drug delivery systems. Major trends in the forecast period include rising adoption of glp-1 receptor agonist therapies, growing focus on peptide-based obesity management, expansion of long-acting injectable peptide formulations, increasing use of combination peptide therapies, rising demand for patient-friendly metabolic treatments.

The increasing prevalence of obesity is expected to drive the growth of the peptide-based metabolic disorders therapeutic market in the coming years. Obesity is a medical condition defined by excessive accumulation of body fat, which poses significant health risks. The rise in obesity cases is attributed to sedentary lifestyles, poor dietary habits, genetic factors, and environmental influences that promote high-calorie diets and limited physical activity. Peptide-based metabolic disorders therapeutics are designed to manage conditions like obesity by utilizing peptides to regulate metabolic processes, enhance insulin sensitivity, and control appetite, thereby improving patient health outcomes and reducing long-term risks associated with these chronic conditions. For example, in December 2024, according to the Office for Health Improvement and Disparities, a UK government agency, the proportion of women living with obesity in early pregnancy was 25.4% from 2022 to 2023, rising slightly to 26.2% from 2023 to 2024. Consequently, the growing prevalence of obesity is propelling the peptide-based metabolic disorders therapeutics market.

Major companies in the peptide-based metabolic disorders therapeutics market are focusing on developing innovative peptide-based treatments, including anti-diabetic biosimilars, to address unmet medical needs and broaden patient treatment options. Peptide-based anti-diabetic biosimilars are therapeutic drugs designed to replicate existing peptide-based therapies for diabetes, providing similar efficacy and safety profiles as established medications while potentially reducing treatment costs through competitive pricing strategies. For example, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Lirafit, a biosimilar version of the widely used anti-diabetic drug Liraglutide in India. It falls under the category of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This class of drugs mimics the function of the naturally occurring GLP-1 hormone, which plays a vital role in regulating blood sugar levels. The biosimilar has undergone clinical trials confirming its effectiveness in reducing glycemic parameters, supporting weight loss, and improving cardiovascular safety. These benefits are essential for managing diabetes and related conditions such as obesity and cardiovascular diseases.

In December 2023, Roche Holding AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche obtains access to its clinical-stage incretins, including CT-388, a dual GLP-1/GIP receptor agonist in Phase 2 trials with potential for treating obesity in both diabetic and non-diabetic patients. Carmot Therapeutics Inc. is a clinical-stage biotechnology company focused on peptide-based therapeutics for metabolic disorders such as diabetes and obesity.

Major companies operating in the peptide based metabolic disorders therapeutics market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Ipsen S.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Amgen Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Amarin Corporation plc

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide based metabolic disorders therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide-based metabolic disorders therapeutics market consists of sales of semaglutide, dulaglutide, albiglutide, and pramlintide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Based Metabolic Disorders Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses peptide based metabolic disorders therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide based metabolic disorders therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide based metabolic disorders therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Liraglutide; Exenatide; Other Drug Type
• 2) By Application: Lysosomal Storage Diseases; Diabetes; Obesity; Hypercholesterolemia; Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Liraglutide: Brand: Saxenda; Brand: Victoza; Generic Liraglutide; Liraglutide For Type 2 Diabetes; Liraglutide For Obesity
• 2) By Exenatide: Brand: Byetta; Brand: Bydureon; Exenatide For Type 2 Diabetes; Extended-Release Exenatide; Generic Exenatide
• 3) By Other Drug Type: Semaglutide; Dulaglutide; Albiglutide; Lixisenatide; GLP-1 Receptor Agonists; Pramlintide; Other Peptide-Based Drugs For Metabolic Disorders
• Companies Mentioned: Novo Nordisk A/S; Eli Lilly and Company; Sanofi S.A.; AstraZeneca PLC; Boehringer Ingelheim International GmbH; Ipsen S.A.; Pfizer Inc.; Merck & Co. Inc.; Johnson & Johnson; AbbVie Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Roche Holding AG; Novartis AG; Bristol-Myers Squibb Company; Vertex Pharmaceuticals Incorporated; Amarin Corporation plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Peptide Based Metabolic Disorders Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Peptide Based Metabolic Disorders Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Peptide Based Metabolic Disorders Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Peptide Based Metabolic Disorders Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Glp-1 Receptor Agonist Therapies
  • 4.2.2 Growing Focus On Peptide-Based Obesity Management
  • 4.2.3 Expansion Of Long-Acting Injectable Peptide Formulations
  • 4.2.4 Increasing Use Of Combination Peptide Therapies
  • 4.2.5 Rising Demand For Patient-Friendly Metabolic Treatments

5. Peptide Based Metabolic Disorders Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals And Clinics
• 5.2 Specialty Diabetes Care Centers
• 5.3 Endocrinology Clinics
• 5.4 Metabolic Disorder Treatment Centers
• 5.5 Homecare Healthcare Providers

6. Peptide Based Metabolic Disorders Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Peptide Based Metabolic Disorders Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Peptide Based Metabolic Disorders Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Peptide Based Metabolic Disorders Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Peptide Based Metabolic Disorders Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Peptide Based Metabolic Disorders Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Peptide Based Metabolic Disorders Therapeutics Market Segmentation

• 9.1. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Liraglutide, Exenatide, Other Drug Type
• 9.2. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
• 9.3. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.4. Global Peptide Based Metabolic Disorders Therapeutics Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity
• 9.5. Global Peptide Based Metabolic Disorders Therapeutics Market, Sub-Segmentation Of Exenatide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide
• 9.6. Global Peptide Based Metabolic Disorders Therapeutics Market, Sub-Segmentation Of Other Drug Type, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders

10. Peptide Based Metabolic Disorders Therapeutics Market Regional And Country Analysis

• 10.1. Global Peptide Based Metabolic Disorders Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Peptide Based Metabolic Disorders Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market

• 11.1. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Peptide Based Metabolic Disorders Therapeutics Market

• 12.1. China Peptide Based Metabolic Disorders Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Peptide Based Metabolic Disorders Therapeutics Market

• 13.1. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Peptide Based Metabolic Disorders Therapeutics Market

• 14.1. Japan Peptide Based Metabolic Disorders Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Peptide Based Metabolic Disorders Therapeutics Market

• 15.1. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Peptide Based Metabolic Disorders Therapeutics Market

• 16.1. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Peptide Based Metabolic Disorders Therapeutics Market

• 17.1. South Korea Peptide Based Metabolic Disorders Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Peptide Based Metabolic Disorders Therapeutics Market

• 18.1. Taiwan Peptide Based Metabolic Disorders Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Peptide Based Metabolic Disorders Therapeutics Market

• 19.1. South East Asia Peptide Based Metabolic Disorders Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Peptide Based Metabolic Disorders Therapeutics Market

• 20.1. Western Europe Peptide Based Metabolic Disorders Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Peptide Based Metabolic Disorders Therapeutics Market

• 21.1. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Peptide Based Metabolic Disorders Therapeutics Market

• 22.1. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Peptide Based Metabolic Disorders Therapeutics Market

• 23.1. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Peptide Based Metabolic Disorders Therapeutics Market

• 24.1. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Peptide Based Metabolic Disorders Therapeutics Market

• 25.1. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market

• 26.1. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Peptide Based Metabolic Disorders Therapeutics Market

• 27.1. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Peptide Based Metabolic Disorders Therapeutics Market

• 28.1. North America Peptide Based Metabolic Disorders Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Peptide Based Metabolic Disorders Therapeutics Market

• 29.1. USA Peptide Based Metabolic Disorders Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Peptide Based Metabolic Disorders Therapeutics Market

• 30.1. Canada Peptide Based Metabolic Disorders Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Peptide Based Metabolic Disorders Therapeutics Market

• 31.1. South America Peptide Based Metabolic Disorders Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Peptide Based Metabolic Disorders Therapeutics Market

• 32.1. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Peptide Based Metabolic Disorders Therapeutics Market

• 33.1. Middle East Peptide Based Metabolic Disorders Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Peptide Based Metabolic Disorders Therapeutics Market

• 34.1. Africa Peptide Based Metabolic Disorders Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Peptide Based Metabolic Disorders Therapeutics Market Regulatory and Investment Landscape

36. Peptide Based Metabolic Disorders Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Peptide Based Metabolic Disorders Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Peptide Based Metabolic Disorders Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Peptide Based Metabolic Disorders Therapeutics Market Company Profiles
  • 36.3.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

37. Peptide Based Metabolic Disorders Therapeutics Market Other Major And Innovative Companies

• Ipsen S.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Amgen Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Amarin Corporation plc

38. Global Peptide Based Metabolic Disorders Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Peptide Based Metabolic Disorders Therapeutics Market

40. Peptide Based Metabolic Disorders Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Peptide Based Metabolic Disorders Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Peptide Based Metabolic Disorders Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Peptide Based Metabolic Disorders Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer